The global antibody optimization service market is projected to grow from USD 2.77 billion in 2024 to USD 6.07 billion by 2034, driven by advances in gene-editing technologies, AI/computational tools, and increasing biologics R&D.

Over 150 pharmaceutical companies are actively developing 170+ pipeline melanoma drugs, with promising therapies in various clinical trial stages targeting improved treatment outcomes through immunotherapies and targeted treatments.

IDEAYA Biosciences reported a Q2 2025 net loss of $0.88 per share with no revenue, but maintained strong cash reserves of $991.9 million. The company continues advancing its cancer therapy pipeline, with key clinical trials progressing in darovasertib and other oncology programs.

The melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.

Kura Sushi USA reported weak Q3 results, missing analyst estimates. Several other companies, including LegalZoom.com, Stardust Power, 10x Genomics, IDEAYA Biosciences, and uniQure, also saw their shares decline in pre-market trading.

Morphic Holding surged 75.1% on news of Eli Lilly's $3.2 billion acquisition. Ideaya Biosciences gained 15.3% after positive phase 2 trial results. Etsy fell 5.3% due to product sale restrictions. Intel jumped 6.2% following positive remarks from Melius Research.

BTIG increased its price target on Ideaya Biosciences to $62 from $55, citing positive data from a Phase 2 study of the company's drug IDE397 as a monotherapy for treating certain cancers.

Paramount Global shares jumped 7.5% in pre-market trading after the company announced a $28 billion merger deal with Skydance Media to create a new entity called 'New Paramount'. Several other stocks also saw significant pre-market movements.

In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.4, a high estimate of $60.00, and a low estimate of $52.00. This current average has increased by 24.02% from the previous average price target of $44.67. Understanding Analyst Ratings: A Comprehensive Breakdown The analysis of recent analyst actions sheds light on the perception of IDEAYA Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robert Driscoll Wedbush Maintains Outperform $52.00 - Yigal Nochomovitz Citigroup Raises Buy $60.00 $40.00 Justin Zelin BTIG Announces Buy $55.00 - Anupam Rama JP Morgan Raises Overweight $57.00 $51.00 Gregory Renza RBC Capital Raises Outperform $53.00 $43.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IDEAYA Biosciences. This information provides ...Full story available on Benzinga.com

In the last three months, 6 analysts have published ratings on IDEAYA Biosciences (NASDAQ:IDYA), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for IDEAYA Biosciences, revealing an average target of $52.33, a high estimate of $57.00, and a low estimate of $43.00. This upward trend is evident, with the current average reflecting a 29.53% increase from the previous average price target of $40.40. Decoding Analyst Ratings: A Detailed Look A comprehensive examination of how financial experts perceive IDEAYA Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Justin Zelin BTIG Announces Buy $55.00 - Anupam Rama JP Morgan Raises Overweight $57.00 $51.00 Gregory Renza RBC Capital Raises Outperform $53.00 $43.00 Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00 Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00 Gregory Renza RBC Capital Raises Outperform $43.00 $36.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related ...Full story available on Benzinga.com

6 analysts have expressed a variety of opinions on IDEAYA Biosciences (NASDAQ:IDYA) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 2 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.5, a high estimate of $53.00, and a low estimate of $36.00. Observing a 25.0% increase, the current average has risen from the previous average price target of $37.20. Breaking Down Analyst Ratings: A Detailed Examination A clear picture of IDEAYA Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gregory Renza RBC Capital Raises Outperform $53.00 $43.00 Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00 Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00 Gregory Renza RBC Capital Raises Outperform $43.00 $36.00 Gregory Renza RBC Capital Maintains Outperform $36.00 - Anupam Rama JP Morgan Raises Overweight $41.00 $35.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com

Analysts' ratings for IDEAYA Biosciences (NASDAQ:IDYA) over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 2 0 0 0 3M Ago 1 2 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.5, a high estimate of $53.00, and a low estimate of $36.00. Marking an increase of 16.49%, the current average surpasses the previous average price target of $38.20. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of IDEAYA Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00 Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00 Gregory Renza RBC Capital Raises Outperform $43.00 $36.00 Gregory Renza RBC Capital Maintains Outperform $36.00 - Anupam Rama JP Morgan Raises Overweight $41.00 $35.00 Robert Driscoll Wedbush Maintains Outperform $43.00 - Vanck Zhu Guggenheim Lowers Buy $44.00 $48.00 Robert Driscoll Wedbush Maintains Outperform $43.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEAYA Biosciences. This information provides ...Full story available on Benzinga.com